Skip to main content
Log in

Prognostic factors for patients with atypical or malignant meningiomas treated at a single center

  • Original Article
  • Published:
Neurosurgical Review Aims and scope Submit manuscript

Abstract

The purpose of this study is to summarize our experience in managing patients with an atypical or malignant meningioma at our institution, with a specific focus on determining the prognostic factors for treatment outcome. We reviewed the records of 126 patients with atypical or malignant meningiomas from January 2001 to August 2011. Data collected included gender, age, Karnofsky Performance Scale (KPS) score, pathology results, cleavability, and bone invasion. The symptoms and signs were recorded for further outcome analysis. There were 37 malignant meningiomas and 89 atypical meningiomas. Total resection (Simpson grade I–II) was achieved in 80.9 % of atypical patients (n = 72) and 67.6 % of malignant patients (n = 25). Forty patients (44.9 %) in the atypical group underwent radiotherapy after surgery, while 26 (70.2 %) patients underwent radiotherapy in the malignant group. The median follow-up duration was 25 months. Patients with a secondary tumor had a much shorter progression-free survival (PFS) than those with a primary tumor in the malignant group. The malignant meningioma group had lower overall survival. Progression-free survival for patients in the malignant group who received postoperative radiotherapy was longer than that for those who did not receive radiotherapy. In conclusion, total resection of the tumor was important because patients with a secondary tumor were much more likely to have recurrence than patients with a primary tumor in the atypical and malignant meningioma groups. Also, radiotherapy should be performed after surgery for a malignant meningioma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Bruna J, Brell M, Ferrer I, Gimenez-Bonafe P, Tortosa A (2007) Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma. Neuropathology 27:114–120

    Article  PubMed  Google Scholar 

  2. Campbell BA, Jhamb A, Maguire JA, Toyota B, Ma R (2009) Meningiomas in 2009: controversies and future challenges. Am J Clin Oncol 32:73–85

    Article  PubMed  Google Scholar 

  3. Ho DM-T, Hsu C-Y, Ting L-T, Chiang H (2002) Histopathology and MIB-1 labeling index predicted recurrence of meningiomas—a proposal of diagnostic criteria for patients with atypical meningioma. Cancer 94:1538–1547

    Article  PubMed  Google Scholar 

  4. Dziuk T, Woo S, Butler EB, Thornby J, Grossman R, Dennis WS, Lu H, Carpenter LS, Chiu JK (1998) Malignant meningioma: an indication for initial aggressive surgery and adjuvant radiotherapy. J Neurooncol 37:177–188

    Article  CAS  PubMed  Google Scholar 

  5. Goyal LK, Suh JH, Mohan DS, Prayson RA, Lee J, Barnett GH (2000) Local control and overall survival in atypical meningioma: a retrospective study. Int J Radiat Oncol Biol Phys 46:57–61

    Article  CAS  PubMed  Google Scholar 

  6. Hug EB, Devries A, Thornton AF, Munzenride JE, Pardo FS, Hedley-Whyte ET, Bussiere MR, Ojemann R (2000) Management of atypical and malignant meningiomas: role of high-dose, 3D-conformal radiation therapy. J Neurooncol 48:151–160

    Article  CAS  PubMed  Google Scholar 

  7. Jaaskelainen J, Haltia M, Servo A (1986) Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol 25:233–242

    Article  CAS  PubMed  Google Scholar 

  8. Kasuya H, Kubo O, Tanaka M, Amano K, Kato K, Hori T (2006) Clinical and radiological features related to the growth potential of meningioma. Neurosurg Rev 29:293–296

    Article  PubMed Central  PubMed  Google Scholar 

  9. Louis DN, Ohgaki H, Wiestler OD (2007) WHO classification of tumors of the central nervous system. IARC, Lyon

    Google Scholar 

  10. Milosevic MF, Frost PJ, Laperriere NJ, Wong CS, Simpson WJ (1996) Radiotherapy for atypical or malignant intracranial meningioma. Int J Radiat Oncol Biol Phys 34:817–822

    Article  CAS  PubMed  Google Scholar 

  11. Modha A, Gutin P (2005) Diagnosis and treatment of atypical and anaplastic meningiomas: a review. Neurosurgery 57:538–550

    Article  PubMed  Google Scholar 

  12. Palma L, Celli P, Franco C, Cervoni L, Cantore G (1997) Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases. J Neurosurg 86:793–800

    Article  CAS  PubMed  Google Scholar 

  13. Pearson BE, Markert JM, Fisher WS, Guthrie BL, Fiveash JB, Palmer CA, Riley K (2008) Hitting a moving target: evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteria. Neurosurg Focus 24:E3

    Article  PubMed  Google Scholar 

  14. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM (1997) Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol 21:1455–1465

    Article  CAS  PubMed  Google Scholar 

  15. Sindou M, Alaywan M (1998) Most intracranial meningiomas are not cleavable tumours: anatomic-surgical evidence and angiographic predictability. Neurosurgery 42:476–480

    Article  CAS  PubMed  Google Scholar 

  16. Vranic A, Popovic M, Cör A, Prestor B, Pizem J (2010) Mitotic count, brain invasion, and location are independent predictors of recurrence-free survival in primary atypical and malignant meningiomas: a study of 86 patients. Neurosurgery 67:1124–1132

    Article  PubMed  Google Scholar 

  17. Whittle IR, Smith C, Navoo P, Collie D (2004) Meningiomas. Lancet 363:1535–1543

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Zhongli Jiang.

Additional information

Comments

Hoi Sang, San Diego, USA

In this manuscript, the authors describe their experience with 89 atypical and 37 malignant meningioma treatments with surgical excision (total excision in 97 patients) with some followed by postoperative irradiation (66 patients). These patients were followed clinically for 2 to 8 years. The conclusions of the study are the following: (1) patients with secondary tumors have a much shorter progression-free survival (PFS) than those with primary tumors in the malignant group, (2) the malignant meningioma patients had a reduced overall survival, and (3) PFS in patients with malignant meningiomas who received postoperative radiotherapy is longer than those who did not receive radiotherapy.

This study is based on the experience of one of the most busy neurosurgical departments in China and is therefore worthy of note. With the detailed analysis of this extensive experience, this manuscript adds further to our knowledge of the natural history of atypical and malignant meningiomas especially in their need for and response to radiotherapy.

Peng Zhao and Mengqing Hu contribute equally to this study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhao, P., Hu, M., Zhao, M. et al. Prognostic factors for patients with atypical or malignant meningiomas treated at a single center. Neurosurg Rev 38, 101–107 (2015). https://doi.org/10.1007/s10143-014-0558-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10143-014-0558-2

Keywords

Navigation